Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00016159 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT00016159: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00016159 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 35 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00016159, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining monoclonal antibody therapy with chemotherapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and monoclonal antibody in treating patients who have acute promyelocytic leukemia.
Interventions
- BIOLOGICAL filgrastim
- DRUG idarubicin
- DRUG tretinoin
- DRUG arsenic trioxide
- BIOLOGICAL lintuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2000-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00016159
The ClinicalTrials.gov registry entry for NCT00016159 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which filgrastim is the first listed.
NCT00016159 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00016159 about?
NCT00016159 is a clinical study titled "Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining monoclonal antibody therapy w...
What is the current status of trial NCT00016159?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2000-11.
What interventions are being tested in trial NCT00016159?
The interventions under investigation include: filgrastim (BIOLOGICAL), idarubicin (DRUG), tretinoin (DRUG), arsenic trioxide (DRUG), lintuzumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00016159?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.